According to Future Market Insights research, during the projected period, the global intranasal corticosteroids market is expected to grow at a CAGR of 5.0%. The market value is projected to increase from US$ 6.8 Billion in 2023 to US$ 11.2 Billion by 2033. The intranasal corticosteroids market was valued at US$ 6.5 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 4.8% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 6.5 Billion |
| Market Value 2023 | US$ 6.8 Billion |
| Market Value 2033 | US$ 11.2 Billion |
| CAGR 2023 to 2033 | 5.0% |
| Market Share of Top 5 Countries | 54.1% |
| Key Market Players | Merck & co., GlaxoSmithKline, AstraZeneca, Sanofi, Perrigo Co., Teva Pharmaceutical Industries, Glenmark Pharmaceuticals, Mylan, Novartis, Pfizer, Pharmascience |
Nasal steroid sprays are a type of medication that delivers corticosteroids directly into the nasal passages to alleviate symptoms associated with nasal allergies, including sneezing and a runny nose. These sprays offer effective relief from hay fever and other nasal allergies, often serving as a viable alternative to oral allergy medications. It usually takes a few days of consistent use for the sprays to take effect. To maintain ongoing relief, it is important to use them daily throughout the allergy season.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for intranasal corticosteroids expanded at a CAGR of close to 4.9% between 2017 and 2022. The intranasal corticosteroids market is around 32.4% of the overall US$ 20.2 Billion global allergy treatment market in 2022.
The global market for intranasal corticosteroids experienced growth over past few decades driven by the increased prevalence of condition like allergic rhinitis and Chronic Obstructive Pulmonary Disease (COPD). This increased prevalence has impacted infants, young children, and the elderly population suffering from these conditions. Most corticosteroids used are for treatment of seasonal allergic rhinitis caused due to aeroallergen.
Companies have been constantly working towards development of products to treat allergy related conditions which are effective yet cost-efficient.
This particular nasal spray has the capability to alleviate three common symptoms associated with allergic rhinitis, namely sneezing, nasal discharge, and nasal congestion.
As a result of these advantageous qualities, there has been a notable rise in the demand for intranasal corticosteroids.
Using a corticosteroid spray consistently on a daily basis is the most effective way to experience its benefits. To reduce symptoms during pollen season, it is recommended to start using the spray at the beginning of the season. It is worth mentioning that nasal corticosteroid sprays are generally safe for adults, and there are specific types that are also safe for children aged 2 and older. Pregnant women can also use corticosteroid sprays safely, but it is important for them to consult with their healthcare provider to choose the options with the best safety record during pregnancy. This ensures that a wider population can benefit from the use of intranasal corticosteroids worldwide.
Prominent companies are actively pursuing acquisitions and expanding their operations to strengthen their product offerings and reach a broader customer base.
The above factors are likely to drive the global market in next few years.
Principal Consultant
Although all intranasal corticosteroids (INCSs) used for treating allergic rhinitis (AR) are generally considered safe and effective, variations in potency, molecular structure, and physicochemical and pharmacokinetic properties can lead to differences in their clinical effectiveness and safety profiles. Some common side effects associated with intranasal corticosteroids include headache, nausea and vomiting, drowsiness, light-headedness, palpitations, loss of taste, wheezing, nosebleeds (epistaxis), nasal ulceration, irritation of the nose and throat (nasopharyngeal irritation), musculoskeletal pain, immunosuppression, and an increased risk of infections.
However, patients with low incomes, especially in developing countries, find it difficult to afford inhaled and intranasal corticosteroids. As a result, they often have no choice but to rely on less effective oral medications.
The USA leads the North America market contributing around US$ 1.9 Billion in 2022.
Prevalence of allergies in the United States is relatively high, with millions of individuals suffering from seasonal and perennial allergies each year. The accessibility and availability of intranasal corticosteroid medications in the USA market contribute to their increased usage. Moreover, healthcare professionals in the USA are well-informed about the benefits of intranasal corticosteroids and frequently prescribe them to patients who require allergy relief.
In the United States, there are currently nine branded Intranasal Corticosteroid products available. Among them, Nasacort Allergy 24HR (triamcinolone acetonide) and Flonase Allergy Relief (fluticasone propionate) are available over the counter. Drug manufacturers are actively working to maximize the therapeutic effects of corticosteroid therapy while minimizing potential systemic adverse effects and improving patient adherence.
Overall, these factors contribute to the higher usage of intranasal corticosteroids in the United States.
In 2022, the China held a dominant share of in the East Asia market and contributed around US$ 466.0 Million.
The increasing urbanization and adoption of Westernized lifestyles in developing countries, along with rapid economic growth, have contributed to a rising trend of AR in recent decades. The prevalence of AR in China varies widely. Additionally, the impact of air pollution and climate change on respiratory disorders cannot be disregarded.
India holds nearly 6.7% market share in the global market in 2022. India is the lucrative market region in the South Asian market in revenue terms in 2022.
Indian subcontinent has witnessed a rise in allergic rhinitis and asthma cases over the past few decades.
India, on a global scale, faces one of the significant levels of air pollution, primarily caused by fossil fuels, vehicular emissions, and biomass. Additionally, the use of incense, mosquito coils, and dhoop sticks contributes significantly to indoor pollution. All these factors cumulatively is expected to boost the global market for intranasal corticosteroids market in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global market for intranasal sprays reached a substantial value of US$ 4.7 Billion in 2022.
Nasal sprays are liquid medications that are administered by spraying them into the nose. They are specifically designed to alleviate discomfort and congestion caused by allergies. Nasal sprays come in two types of containers: pressurized canisters and pump bottles. Some commonly known examples of nasal sprays include Naselin Nasal Spray, Astelin, Astepro, Nazal Spray, Vicks Ultra Fine Mist, Otrivin Spray, and Sinarest Spray.
During year 2022, Allergic rhinitis accounts for around 58.1% of the global market share. Intranasal corticosteroid (INCS) therapy is considered the preferred treatment option for allergic rhinitis (AR) as it effectively inhibits the degranulation of mast cells. While these sprays are generally safe to use, they are not typically recommended as the first-line therapy for allergic rhinitis due to their lower effectiveness in relieving symptoms compared to antihistamines or intranasal corticosteroids. Additionally, their dosing schedule of three or four times daily can be inconvenient.
Fluticasone Propionate accounts for 25.3% of the global market share in 2022.
Fluticasone Propionate helps reduce airway inflammation, thus improving breathing followed by reduced symptoms like coughing, shortness of breath and wheezing. It is also available as a nasal spray for the treatment of allergic rhinitis.
Fluticasone Propionate is considered an effective and commonly prescribed medication for respiratory conditions, and it is available in various brand names and forms. However, it should only be used under medical supervision and as prescribed by a healthcare professional.
Retail pharmacies captured a significant market share of around 31.7% in 2022. Retail pharmacies have established a strong presence with numerous conveniently located branches in various neighbourhoods and communities. This widespread accessibility ensures that customers can easily purchase nasal corticosteroids without the need to travel long distances or wait for delivery. Secondly, these pharmacies are staffed with well-trained pharmacists who are capable of providing valuable guidance and recommendations to customers regarding the use of nasal corticosteroids. This personalized advice instils confidence in customers and empowers them to make informed decisions about their healthcare.
In the market for intranasal corticosteroids, key players are implementing various strategies to increase their sales and generate revenue.
Bayer Healthcare LLC received FDA approval on June 17, 2021, for the nonprescription use of Astepro. This approval allows allergy sufferers to use the nasal sprays without the assistance of a healthcare provider when needed.
Similarly, recent developments related to the company’s manufacturing the Intranasal Corticosteroids have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and MEA |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Indication, Dosage Form, Drug, Distribution Channel, Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The primary consumer for Intranasal Corticosteroids is the allergy and asthma industry.
The United States is poised to stay attractive, projecting a US$ 1.5 billion market by 2033.
The market is estimated to secure a valuation of US$ 6.8 billion in 2023.
The market is estimated to reach US$ 11.2 billion by 2033.
The allergy and asthma sector holds high revenue potential.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Value Added Insights 4.1. Product Adoption / Usage Analysis 4.2. Disease Epidemiology 4.3. Pipeline Assessment 4.4. Recent Product Approvals/Launches 4.5. Regulatory Landscape 4.6. Value Chain Analysis 4.7. Porter’s Analysis 4.8. PESTLE Analysis, By Region 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Per-Capita spend on Intranasal Corticosteroids 5.2.2. Increasing Prevalence of Allergic Rhinitis 5.2.3. Percentage of Population suffering from Allergic Rhinitis opting for Intranasal Corticosteroids 5.2.4. Percentage of Population suffering from Non-Allergic Rhinitis using Intranasal Corticosteroids 5.2.5. Product Adoption/Usage Rate 5.2.6. Growing Product Awareness and Demand in emerging markets 5.2.7. Growing R&D by marketers 5.2.8. New Product Launches 5.2.9. Cost of Product 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value Analysis, 2017 to 2022 6.2. Current and Future Market Value Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug 7.1. Introduction/ Key Findings 7.2. Historical Market Size (US$ Million) Analysis by Drug 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033 7.3.1. Fluticasone Propionate 7.3.2. Budesonide 7.3.3. Beclomethasone Dipropionate 7.3.4. Mometasone Furoate 7.3.5. Triamcinolone Acetonide 7.3.6. Ciclesonide 7.3.7. Flunisolide 7.3.8. Tixocortol 7.4. Market Attractiveness Analysis By Drug 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Value Analysis By Indication, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 8.3.1. Allergic Rhinitis (AR) 8.3.1.1. Seasonal AR 8.3.1.2. Perennial AR 8.3.2. Non-Allergic Rhinitis (NAR) 8.3.2.1. Infectious NAR 8.3.2.2. Vasomotor NAR 8.3.2.3. Atrophic NAR 8.4. Market Attractiveness Analysis By Indication 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033 9.3.1. Intranasal Drops 9.3.2. Intranasal Sprays 9.4. Market Attractiveness Analysis By Dosage Form 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospitals 10.3.2. Retail Pharmacies 10.3.3. Drug Stores 10.3.4. Online Pharmacies 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis by Region, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa 11.4. Market Attractiveness Analysis By Region 12. North America s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 12.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Drug 12.3.3. By Indication 12.3.4. By Dosage Form 12.3.5. Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug 12.4.3. By Indication 12.4.4. By Dosage Form 12.4.5. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Drug 12.8.1.2.2. By Indication 12.8.1.2.3. By Dosage Form 12.8.1.2.4. By Distribution Channel 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Drug 12.8.2.2.2. By Indication 12.8.2.2.3. By Dosage Form 12.8.2.2.4. By Distribution Channel 13. Latin America s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 13.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug 13.3.3. By Indication 13.3.4. By Dosage Form 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug 13.4.3. By Indication 13.4.4. By Dosage Form 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Brazil Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug 13.8.1.2.2. By Indication 13.8.1.2.3. By Dosage Form 13.8.1.2.4. By Distribution Channel 13.8.2. Mexico Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug 13.8.2.2.2. By Indication 13.8.2.2.3. By Dosage Form 13.8.2.2.4. By Distribution Channel 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Drug 13.8.3.2.2. By Indication 13.8.3.2.3. By Dosage Form 13.8.3.2.4. By Distribution Channel 14. Europe s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 14.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug 14.3.3. By Indication 14.3.4. By Dosage Form 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug 14.4.3. By Indication 14.4.4. By Dosage Form 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug 14.8.1.2.2. By Indication 14.8.1.2.3. By Dosage Form 14.8.1.2.4. By Distribution Channel 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug 14.8.2.2.2. By Indication 14.8.2.2.3. By Dosage Form 14.8.2.2.4. By Distribution Channel 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug 14.8.3.2.2. By Indication 14.8.3.2.3. By Dosage Form 14.8.3.2.4. By Distribution Channel 14.8.4. UK Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Drug 14.8.4.2.2. By Indication 14.8.4.2.3. By Dosage Form 14.8.4.2.4. By Distribution Channel 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Drug 14.8.5.2.2. By Indication 14.8.5.2.3. By Dosage Form 14.8.5.2.4. By Distribution Channel 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Drug 14.8.6.2.2. By Indication 14.8.6.2.3. By Dosage Form 14.8.6.2.4. By Distribution Channel 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Drug 14.8.7.2.2. By Indication 14.8.7.2.3. By Dosage Form 14.8.7.2.4. By Distribution Channel 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 15.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Drug 15.3.3. By Indication 15.3.4. By Dosage Form 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug 15.4.3. By Indication 15.4.4. By Dosage Form 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug 15.8.1.2.2. By Indication 15.8.1.2.3. By Dosage Form 15.8.1.2.4. By Distribution Channel 15.8.2. Thailand Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug 15.8.2.2.2. By Indication 15.8.2.2.3. By Dosage Form 15.8.2.2.4. By Distribution Channel 15.8.3. Indonesia Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug 15.8.3.2.2. By Indication 15.8.3.2.3. By Dosage Form 15.8.3.2.4. By Distribution Channel 15.8.4. Malaysia Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Drug 15.8.4.2.2. By Indication 15.8.4.2.3. By Dosage Form 15.8.4.2.4. By Distribution Channel 16. East Asia s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 16.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug 16.3.3. By Indication 16.3.4. By Dosage Form 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug 16.4.3. By Indication 16.4.4. By Dosage Form 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug 16.8.1.2.2. By Indication 16.8.1.2.3. By Dosage Form 16.8.1.2.4. By Distribution Channel 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug 16.8.2.2.2. By Indication 16.8.2.2.3. By Dosage Form 16.8.2.2.4. By Distribution Channel 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug 16.8.3.2.2. By Indication 16.8.3.2.3. By Dosage Form 16.8.3.2.4. By Distribution Channel 17. Oceania s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 17.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug 17.3.3. By Indication 17.3.4. By Dosage Form 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug 17.4.3. By Indication 17.4.4. By Dosage Form 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug 17.8.1.2.2. By Indication 17.8.1.2.3. By Dosage Form 17.8.1.2.4. By Distribution Channel 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug 17.8.2.2.2. By Indication 17.8.2.2.3. By Dosage Form 17.9. By Distribution Channel 18. Middle East and Africa s Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2017 to 2022 18.3. Current and Future Market size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. Northern Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Drug 18.3.3. By Indication 18.3.4. By Dosage Form 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug 18.4.3. By Indication 18.4.4. By Dosage Form 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug 18.8.1.2.2. By Indication 18.8.1.2.3. By Dosage Form 18.8.1.2.4. By Distribution Channel 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug 18.8.2.2.2. By Indication 18.8.2.2.3. By Dosage Form 18.8.2.2.4. By Distribution Channel 18.8.3. Northern Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Drug 18.8.3.2.2. By Indication 18.8.3.2.3. By Dosage Form 18.8.3.2.4. By Distribution Channel 18.8.4. South Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Drug 18.8.4.2.2. By Indication 18.8.4.2.3. By Dosage Form 18.8.4.2.4. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market concentration 19.3. Market Share Analysis of Top Players (%) 19.4. Market Presence Analysis 19.4.1. Regional Footprint of Players 19.4.2. Method Footprint of Players 19.4.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Branding and Promotional Strategies, By Key Players 20.3. Key Development Analysis 20.4. Competition Deep Dive 20.4.1. GlaxoSmithKline 20.4.1.1. Overview 20.4.1.2. Product Portfolio 20.4.1.3. SWOT Analysis 20.4.1.4. Key Development 20.4.1.5. Sales Footprint 20.4.1.6. Strategy Overview 20.4.1.6.1. Marketing Strategies 20.4.1.6.2. Product Strategies 20.4.1.6.3. Channel Strategies 20.4.2. AstraZeneca 20.4.2.1. Overview 20.4.2.2. Product Portfolio 20.4.2.3. SWOT Analysis 20.4.2.4. Key Development 20.4.2.5. Sales Footprint 20.4.2.6. Strategy Overview 20.4.2.6.1. Marketing Strategies 20.4.2.6.2. Product Strategies 20.4.2.6.3. Channel Strategies 20.4.3. Sanofi 20.4.3.1. Overview 20.4.3.2. Product Portfolio 20.4.3.3. SWOT Analysis 20.4.3.4. Key Development 20.4.3.5. Sales Footprint 20.4.3.6. Strategy Overview 20.4.3.6.1. Marketing Strategies 20.4.3.6.2. Product Strategies 20.4.3.6.3. Channel Strategies 20.4.4. Perrigo Co. 20.4.4.1. Overview 20.4.4.2. Product Portfolio 20.4.4.3. SWOT Analysis 20.4.4.4. Key Development 20.4.4.5. Sales Footprint 20.4.4.6. Strategy Overview 20.4.4.6.1. Marketing Strategies 20.4.4.6.2. Product Strategies 20.4.4.6.3. Channel Strategies 20.4.5. Teva Pharmaceutical Industries 20.4.5.1. Overview 20.4.5.2. Product Portfolio 20.4.5.3. SWOT Analysis 20.4.5.4. Key Development 20.4.5.5. Sales Footprint 20.4.5.6. Strategy Overview 20.4.5.6.1. Marketing Strategies 20.4.5.6.2. Product Strategies 20.4.5.6.3. Channel Strategies 20.4.6. Glenmark Pharmaceuticals 20.4.6.1. Overview 20.4.6.2. Product Portfolio 20.4.6.3. SWOT Analysis 20.4.6.4. Key Development 20.4.6.5. Sales Footprint 20.4.6.6. Strategy Overview 20.4.6.6.1. Marketing Strategies 20.4.6.6.2. Product Strategies 20.4.6.6.3. Channel Strategies 20.4.7. Mylan 20.4.7.1. Overview 20.4.7.2. Product Portfolio 20.4.7.3. SWOT Analysis 20.4.7.4. Key Development 20.4.7.5. Sales Footprint 20.4.7.6. Strategy Overview 20.4.7.6.1. Marketing Strategies 20.4.7.6.2. Product Strategies 20.4.7.6.3. Channel Strategies 20.4.8. Novartis 20.4.8.1. Overview 20.4.8.2. Product Portfolio 20.4.8.3. SWOT Analysis 20.4.8.4. Key Development 20.4.8.5. Sales Footprint 20.4.8.6. Strategy Overview 20.4.8.6.1. Marketing Strategies 20.4.8.6.2. Product Strategies 20.4.8.6.3. Channel Strategies 20.4.9. Pfizer 20.4.9.1. Overview 20.4.9.2. Product Portfolio 20.4.9.3. SWOT Analysis 20.4.9.4. Key Development 20.4.9.5. Sales Footprint 20.4.9.6. Strategy Overview 20.4.9.6.1. Marketing Strategies 20.4.9.6.2. Product Strategies 20.4.9.6.3. Channel Strategies 20.4.10. Pharmascience 20.4.10.1. Overview 20.4.10.2. Product Portfolio 20.4.10.3. SWOT Analysis 20.4.10.4. Key Development 20.4.10.5. Sales Footprint 20.4.10.6. Strategy Overview 20.4.10.6.1. Marketing Strategies 20.4.10.6.2. Product Strategies 20.4.10.6.3. Channel Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Intranasal Corticosteroids Market
